318 results
8-K
EX-99.2
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness
8-K
EX-10.1
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
responsibility against such losses and risks and in such amounts as are prudent in the businesses in which the Company and the Subsidiaries are engaged
8-K
EX-1.1
LEXX
Lexaria Bioscience Corp
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
responsibility for the accuracy or completeness of the Offering Documents or the Information and such other information; and (c) will not make an appraisal … deliverables included in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company with responsibility for financial
8-K
EX-99.1
shboie 028
16 Feb 24
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:30pm
424B5
5on83
16 Feb 24
Prospectus supplement for primary offering
6:01am
8-K
EX-99.1
v7p urlprugeo
24 Jan 24
Regulation FD Disclosure
2:12pm
S-8
EX-4.1
w0y iwy4l
18 Jan 24
Registration of securities for employees
2:38pm
8-K
EX-99.1
mlg8xw2e
4 Jan 24
Lexaria’s Patented Technology Improved the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide
5:07pm
8-K
EX-99
cyz1a k63ai
16 Oct 23
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
1:13pm
8-K
EX-99.1
gppkbmv 4c66
12 Oct 23
Lexaria Granted Two New Patents in Canada
3:57pm
8-K
EX-10.1
q6xc5lekzzqb nacjx
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-1.1
e84kzj6tl
3 Oct 23
Entry into a Material Definitive Agreement
4:05pm
424B5
t1gz qh0y9
2 Oct 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
c02ke5vf5igikwr4mdm
28 Jul 23
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
12:11pm
8-K
EX-99.1
k79jucwm8jbw90d
10 May 23
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
5:16pm
8-K
EX-10.2
5lqyul4nt6as1
10 May 23
Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
5:16pm